Adnexus Therapeutics

Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering

Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering

August 21, 2007

Waltham, MA – August 21, 2007 – Adnexus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All shares in the offering will be sold by Adnexus.

The book-running managers of the proposed offering will be Lehman Brothers and UBS Securities LLC, and Cowen and Company and Lazard Freres & Co LLC will serve as co-managers.

Color Kinetics

Philips Completes Acquisition of US-Based Color Kinetics, Further Strengthening Leading Position in LED Lighting Systems, Components and Technologies

Philips Completes Acquisition of US-Based Color Kinetics, Further Strengthening Leading Position in LED Lighting Systems, Components and Technologies

August 27, 2007

AMSTERDAM, The Netherlands and BURLINGTON, Mass., Aug. 27 /PRNewswire/ -- Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced it has completed its acquisition of Color Kinetics Incorporated, a leader in designing and marketing innovative lighting systems based on Light Emitting Diode (LED) technology. As a result of the transaction, Color Kinetics will be financially consolidated with immediate effect within the Luminaires business group of Philips' Lighting division.

Ensemble Therapeutics Corporation

Ensemble Discovery Names Michael D. Taylor, PhD as President and Chief Executive Officer

Ensemble Discovery Names Michael D. Taylor, PhD as President and Chief Executive Officer

September 4, 2007

Cambridge, MA (September 4, 2007) — Ensemble Discovery Corporation, a biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry™ (DPC™) platform, today announced that it has appointed Michael D. Taylor, Ph.D. as President and Chief Executive Officer and to the company’s Board of Directors.

Epitome Biosystems

Epitome Biosystems Names Edward Machuga Vice President Sales and Marketing

Epitome Biosystems Names Edward Machuga Vice President Sales and Marketing

September 12, 2007

WALTHAM, MA - September 12, 2007 -- Epitome Biosystems, a leader in quantitative protein measurement solutions, announced today the appointment of Edward Machuga to Vice President, Sales and Marketing. In this newly created position, Mr. Machuga will be responsible for all commercial activities, including sales of the newly launched Ti-Tyr™ Profiling Chip and Q-SONAR™ Discovery Service, as well as other products that will emerge from Epitome’s pipeline. Mr.

Adnexus Therapeutics

Bristol-Myers Squibb to Acquire Adnexus Therapeutics

Bristol-Myers Squibb to Acquire Adnexus Therapeutics

September 24, 2007

Bristol-Myers Squibb to advance biologics strategy through targeted biologics acquisition

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals to Utilize Peptech’s Breakthrough Technology to “Humanise” Internal Drug Candidates

AVEO Pharmaceuticals to Utilize Peptech’s Breakthrough Technology to “Humanise” Internal Drug Candidates

October 2, 2007

October 2, 2007, Sydney, Australia and Cambridge, MA – Peptech Limited (ASX: PTD) and AVEO Pharmaceuticals Inc. today announced they have entered into a non-exclusive research and commercialisation agreement in which AVEO will access Peptech’s SuperhumanisationTM technology to humanise internally-derived drug candidates.

AVEO Pharmaceuticals, Inc.

OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration

OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration

October 2, 2007

OSI to Host Conference Call / Webcast

Helicos BioSciences Corporation

Helicos Promotes Steve Lombardi to President

Helicos Promotes Steve Lombardi to President

October 3, 2007

Stan Lapidus Appointed Chairman of the Board of Directors

BIND Therapeutics, Inc.

BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy

BIND Biosciences, Inc. Awarded NIH Phase I SBIR Contract to Develop Therapeutic Targeted Nanoparticles for Prostate Cancer Therapy

October 8, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company focused on developing therapeutic targeted nanoparticles, announced today that it has been awarded a six month $150,000 Phase I SBIR contract from the National Cancer Institute (NCI) to develop a targeted therapy for hormone refractory prostate cancer (HRPC). Prostate cancer accounts for an estimated 27,000 annual deaths in the U.S. and is an area of enormous unmet medical need.

LS9

LS9, Inc. Secures $15 Million in Series B Funding

LS9, Inc. Secures $15 Million in Series B Funding

October 8, 2007

Funding By Lightspeed Venture Partners, Flagship Ventures and Khosla Ventures

LS9, Inc., the Renewable Petroleum Company™, announces the close of its second round of funding with $15 million in new investments. Leading the financing was Lightspeed Venture Partners, with additional contributions from existing partners Flagship Ventures and Khosla Ventures. The funding will support the company’s continued talent acquisition and rapid commercialization of DesignerBiofuels™ products.